Nicotinamide adenine dinucleotide

2 papers1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: National Institute on Aging and 1 more

Cells1

Outcomes

Lifespan

is required forin yeast cells1

1 study

Nicotinamide adenine dinucleotide is required for lifespan in yeast cells.
“Lifespan extension in a mutant with reduced PKA activity requires Sir2 and NAD (nicotinamide adenine dinucleotide).”
Cellsin a mutant with reduced PKA activity
Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration
Nature18 Jul 2002

Funding

2 grants since 2025

National Institute on AgingUS$1.6mNational Institute of Diabetes and Digestive and Kidney DiseasesUS$190k

Latest

37 in 12 months

JAMA8 Oct

Nicotinamide riboside did not improve early Parkinson disease

In a 52-week randomised trial, disease rating scores rose by 2.45 points with the supplement compared with a 0.27-point fall with placebo.In a 52-week randomised trial, disease rating scores rose by 2.45 points with the supplement compared with a 0.27-point fall with placebo.

Randomised trial in 393 peopleNicotinamide riboside

Paper

Frontiers in Nutrition8 Oct